Knight Therapeutics (TSE:GUD - Free Report) had its price target boosted by Stifel Nicolaus from C$5.40 to C$5.75 in a report released on Friday, BayStreet.CA reports.
GUD has been the subject of a number of other research reports. Raymond James boosted their price objective on Knight Therapeutics from C$7.00 to C$7.50 and gave the company an outperform rating in a research report on Wednesday, March 6th. Royal Bank of Canada raised their price objective on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the company an outperform rating in a research report on Friday, March 22nd.
Check Out Our Latest Stock Analysis on GUD
Knight Therapeutics Stock Down 2.6 %
Shares of TSE:GUD traded down C$0.16 during trading on Friday, hitting C$5.94. The company's stock had a trading volume of 90,740 shares, compared to its average volume of 71,251. Knight Therapeutics has a fifty-two week low of C$4.35 and a fifty-two week high of C$6.17. The stock's 50-day moving average price is C$5.58 and its two-hundred day moving average price is C$5.38. The company has a debt-to-equity ratio of 9.25, a quick ratio of 1.79 and a current ratio of 3.20. The company has a market capitalization of C$600.95 million, a PE ratio of -37.13, a PEG ratio of -1,013.50 and a beta of 0.49.
Knight Therapeutics (TSE:GUD - Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.05). Knight Therapeutics had a negative return on equity of 2.14% and a negative net margin of 5.13%. The firm had revenue of C$74.20 million for the quarter, compared to the consensus estimate of C$78.37 million. As a group, sell-side analysts expect that Knight Therapeutics will post 0.0602815 EPS for the current year.
Insider Transactions at Knight Therapeutics
In related news, insider Sime Armoyan purchased 351,000 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The stock was acquired at an average price of C$5.25 per share, for a total transaction of C$1,842,750.00. 46.44% of the stock is owned by insiders.
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
See Also
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
